Linezolid resistance in a clinical isolate of Staphylococcus aureus

被引：853

作者：

Tsiodras, S

Gold, HS

Sakoulas, G

Eliopoulos, GM

Wennersten, C

Venkataraman, L

Moellering, RC

Ferraro, MJ

机构：

[1] Massachusetts Gen Hosp, Dept Pathol, Clin Microbiol Labs, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA

[3] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA

[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

来源：

LANCET | 2001年 / 358卷 / 9277期

关键词：

D O I：

10.1016/S0140-6736(01)05410-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.

引用

页码：207 / 208

页数：2

共 5 条

[1] Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [J].